MeiraGTx closes initial $200M Hologen collaboration; Hologen to own 70% of neuro JV

MeiraGTx Holdings plc

Completed initial closing of strategic collaboration with Hologen on April 20, 2026; Hologen provided $200M upfront cash payment.
Hologen to fund remaining portion of upfront via post-completion share purchases, ultimately owning 70% of HNAI and minority stake in MeiraGTx Manufacturing.
Collaboration covers AAV-GAD for Parkinson's disease, AAV-BDNF for genetic obesity disorders, and proprietary CNS delivery device.
MeiraGTx Neuro UK retains 30% of HNAI; Hologen gets exclusive option to buy up to 40% of MeiraGTx Manufacturing shares within 12 months.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MeiraGTx Holdings plc entered into Collaboration Agreement with Hologen Neuro AI UK Limited and Hologen Limited and Hologen Neuro AI Limited (effective 2026-04-20).

Action: entry
Agreement: collaboration
Counterparty: Hologen Neuro AI UK Limited and Hologen Limited and Hologen Neuro AI Limited
Effective: 2026-04-20

Exact text from the filing

the Company, MeiraGTx Neuro UK, MeiraGTx Neuro I, LLC, a Delaware limited liability company (“MeiraGTx Neuro US”), Hologen, HNAI and Hologen Neuro AI UK Limited, a private company limited by shares incorporated in England (“HNAI UK”), entered into the Collaboration and License Agreement (the “Collaboration Agreement”), for the research, development, manufacture and commercialization of the Company’s (i) AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for the treatment of genetic obesity disorders and other potential locally delivered genetic medicines to the central nervous system (the “Clinical Programs”) and (ii) proprietary device designed to effect the local delivery of a gene therapy product into the central nervous system or any topographic or subcutaneous tissue modification on the face and scalp, of humans or animals (the “Delivery Device”), in each case, in accordance with the terms and conditions of the Coll

View on SEC.gov

Browse all material agreements →

MeiraGTx Holdings plc filing history →

Source: SEC EDGAR

accession 0001104659-26-048196

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.